Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals. The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world. Read More
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around $9.53 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 9.2% above analysts’ consensus estimates.
IDEXX Laboratories (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, has sent ripples through the financial markets with an astounding 27.5% surge in its stock price. This remarkable leap was ignited by the company's stellar second-quarter earnings report, which not only shattered Wall Street's profit and sales
Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals.
These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over time.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call.
